地舒单抗治疗骨质疏松期间感染风险:系统评价与Meta分析
该系统评价与Meta分析纳入33项随机对照试验共22253例患者,评估地舒单抗60mg每6个月方案与任何对照相比的严重感染不良事件风险。结果显示地舒单抗组严重感染不良事件发生率更高(RR 1.21;95%CI 1.04-1.40;I²=0%),主要来自耳鼻喉和胃肠道感染,但任何感染和感染相关死亡率与对照组相当。
要点
- 地舒单抗60mg每6个月治疗组严重感染不良事件发生率高于对照组(RR 1.21;95%CI 1.04-1.40;I²=0%)。
- 严重感染不良事件主要来自耳鼻喉(RR 2.66;95%CI 1.20-5.91)和胃肠道(RR 1.43;95%CI 1.02-2.01)。
- 任何感染(RR 1.03;95%CI 0.99-1.06)和感染相关死亡率(RR 0.50;95%CI 0.20-1.23)与对照组相当。
核心结论
- 地舒单抗以骨质疏松剂量治疗时严重感染不良事件发生率更高,但任何感染和感染相关死亡率与对照组相似,作者认为治疗开始前应考虑这些发现。
研究设计与样本
- 系统评价与Meta分析,检索PubMed和Cochrane对照试验中心注册库至2019年5月27日,纳入所有地舒单抗60mg每6个月与任何对照比较的随机对照试验,排除癌症患者预防骨相关事件的试验,共纳入33项研究22253例患者。
主要发现
- 地舒单抗组与任何对照相比严重感染不良事件发生率更高(RR 1.21;95%CI 1.04-1.40;I²=0%)。
- 严重感染不良事件主要来自耳鼻喉(RR 2.66;95%CI 1.20-5.91)和胃肠道(RR 1.43;95%CI 1.02-2.01)。
- 基于充分分配隐藏的敏感性分析中RR相似。
- 任何感染(RR 1.03;95%CI 0.99-1.06)和感染相关死亡率(RR 0.50;95%CI 0.20-1.23)在组间相当。
关键数值与推荐
- 地舒单抗60mg每6个月方案与任何对照相比严重感染不良事件RR 1.21(95%CI 1.04-1.40;I²=0%)。
- 耳鼻喉来源严重感染不良事件RR 2.66(95%CI 1.20-5.91)。
- 胃肠道来源严重感染不良事件RR 1.43(95%CI 1.02-2.01)。
- 任何感染RR 1.03(95%CI 0.99-1.06)。
- 感染相关死亡率RR 0.50(95%CI 0.20-1.23)。
临床怎么用
- 作者认为这些发现值得在开始治疗前考虑。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Denosumab inhibits the receptor activator of nuclear factor κ-Β ligand, an immune system modulator. Safety endpoints including risk for infections were assessed as secondary outcomes in randomized controlled trials (RCTs) of the drug. OBJECTIVE: To assess the risk of serious adverse events of infections (SAEI) in denosumab-treated patients. DATA SOURCES: PubMed and Cochrane Central Register of Controlled Trials were searched up to May 27, 2019. STUDY SELECTION: All RCTs of denosumab (60 mg every 6 months) versus any comparator were included. We excluded trials in cancer patients for prevention of skeletal-related events. DATA EXTRACTION: Two reviewers independently applied selection criteria and extracted the data. Risk ratios (RR) with 95% confidence intervals (CI) were pooled using a fixed effect model. Sensitivity analysis was based on risk of bias. DATA SYNTHESIS: Thirty-three studies (22 253 patients) were included. There was a higher incidence of SAEI during denosumab treatment versus any comparator (RR, 1.21; 95% CI, 1.04-1.40; I2 = 0%), mainly of ear, nose, and throat (RR, 2.66; 95% CI, 1.20-5.91) and gastrointestinal origin (RR, 1.43; 95% CI, 1.02-2.01). RR was similar in a sensitivity analysis based on adequate allocation concealment. The RR of any infection (RR, 1.03; 95% CI, 0.99-1.06) and infection-related mortality (RR, 0.50; 95% CI, 0.20-1.23) was comparable between groups. CONCLUSIONS: A higher incidence of SAEI is demonstrated during treatment with denosumab in an osteoporosis dose. Nevertheless, the overall risk for any infection or related mortality is similar to comparator groups. These findings merit consideration before therapy initiation.
引用
- Diker-Cohen T, Rosenberg D, Avni T, et al. Risk for Infections During Treatment With Denosumab for Osteoporosis: A Systematic Review and Meta-analysis. J Clin Endocrinol Metab. 2020. PMID: 31899506. doi:10.1210/clinem/dgz322
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。